Nachrichten zur Fate Therapeutics, Inc. Aktie

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.…

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…

Fate Therapeutics prices stock offering at $5.50 per share By Investing.com

Fate Therapeutics prices stock offering at $5.50 per share…

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

…

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.…

RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

RADNOR, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…

SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated…

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

…

SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of…

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to…

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), National Vision Holdings, Inc. (NASDAQ: EYE)

NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC)…

The Latest Analyst Ratings for Fate Therapeutics

Latest Ratings for FATE DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyMaintainsEqual-Weight Dec 2021WedbushUpgradesNeutralOutperform …

Form 8-K FATE THERAPEUTICS INC For: Aug 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of Fate Therapeutics Soared This Week

The companys shares bounced back after a stock sale last week....…

Form 8-K FATE THERAPEUTICS INC For: Jun 06

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K FATE THERAPEUTICS INC For: Jun 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K FATE THERAPEUTICS INC For: Jun 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Insiderhandel: Aufsichtsrat kauft Aktien von Fate Therapeutics im Wert von 1.586.029$

Redmile Group, LLC - Aufsichtsrat - Tag der Transaktion: 2023-04-21...…

Insiderhandel: Aufsichtsrat kauft Aktien von Fate Therapeutics im Wert von 119.800$

Redmile Group, LLC - Aufsichtsrat - Tag der Transaktion: 2023-04-20...…

Form 8-K FATE THERAPEUTICS INC For: Apr 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat kauft Aktien von Fate Therapeutics im Wert von 154.200$

Redmile Group, LLC - Aufsichtsrat - Tag der Transaktion: 2023-04-14...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Fate Therapeutics im Wert von 1.765.660$

Redmile Group, LLC - Aufsichtsrat - Tag der Transaktion: 2023-04-14...…

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023

New York, New York--(Newsfile Corp. - March 10, 2023) - The law firm of Kirby McInerney LLP announces that a…

Fate Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE),…

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do…

Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables...…

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE

New York, New York--(Newsfile Corp. - February 23, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds…

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - February 23, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds…

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the…

Fate Class Action: Levi & Korsinsky Reminds Fate Therapeutics, Inc. Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of March 22, 2023 - FATE

New York, New York--(Newsfile Corp. - February 22, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc.…

Fate Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Boston, Massachusetts--(Newsfile Corp. - February 22, 2023) - Block & Leviton announces that a class action lawsuit has been filed…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)

NEW YORK, Feb. 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics,…

FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed…

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - February 20, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. (NASDAQ:…

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK, Feb. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

New York, New York--(Newsfile Corp. - February 18, 2023) - Pomerantz LLP announces that a class action lawsuit has been…

FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES, Feb. 17, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses…

Fate Class Action: Levi & Korsinsky Reminds Fate Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 22, 2023 - FATE

New York, New York--(Newsfile Corp. - February 16, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc.…

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the…